sector medic suppli devic
 underwhelm vision
messag turn underwhelm sale come shi
consensu vision surgic segment miss meanwhil although
ep beat upsid came line driven lower tax interest
expens manag reiter full year revenu guidanc continu
express confid long-term growth trend underpin contact len market
expect investor concern come quarter moder daili sih
growth especi increas competit right around corner share
fulli valu current level view maintain neutral rate
disappoint csi come short revenu
pro forma miss consensu adjust ep
yoy came ahead street expect without benefit lower tax rate
howev estim ep would miss consensu recent
momentum stall across busi pro forma csi
pro forma deceler respect rel tougher
comp one-tim item contribut top line slowdown shortfal
daili len categori paragard like rais red flag investor view given
import product long-term growth
coopervis sale pro forma came consensu
growth mark deceler trend pro forma quarter
perform come yoy comp tougher categori
perspect single-us sphere cc multifoc cc drove
miss come street respect mark
second quarter single-digit growth daili sphere segment past four
year coupl alc recent comment stabil extend wear
categori could lead concern whether shift daili underpin
much contact len market growth recent year begin slow manag
emphat case new fit data point continu adopt
howev anoth tough comp tap daili segment new
competit way follow alcon recent approv trend
someth keep eye go forward
elsewher toric cc non single-us sphere
categori cc came modestli ahead street expect
latter categori includ emerg specialti len portfolio myopia
manag continu talk ahead potenti fda approv misit len later
year geograph basi intern busi deceler
sequenti continu strength asia pacif cc off-set
slowdown emea cc driven reduc stock region prepar possibl
brexit-rel headwind meanwhil america growth cc flat sequenti
estim silicon hydrogel len sale rose
forecast growth driven compani daili sih lens
clariti myday yoy ex-fx cc growth impress
vacuum mark signific deceler cc growth first half year
repres slowest growth segment sinc began break five
year ago see figur meanwhil compani extend wear sih portfolio biofin
avaira grew cc manag reiter
revenu guidanc underli growth still peg model call
coopervis revenu come cc continu
page analyst certif import disclosur
estim global len sale rose cc calendar
market slowest quarterli growth rate three year four major
manufactur combin sale yoy report basi alcon
 lost share sequenti bausch
gain ground vs biggest share donor yoy basi give
rel biggest beneficiari loss
alcon bausch also make increment headway
contact len growth clearli moder past year market remain healthi
overal continu outperform backdrop compani
trail underli growth rate stand vs competitor
see world-wide contact len growth settl outlook
remain rel stabl share perspect believ cooper
remain well posit benefit daili len adopt increas silicon hydrogel
penetr model call compani remain net share taker
increas daili sih competit dynam keep eye move forward
howev alcon bausch pois roll new product segment
next month extent alcon drive acceler contact
len growth particular interest biggest laggard space
past year
compani report guggenheim secur llc estim
compani report guggenheim secur llc estim
meanwhil coopersurg revenu pro forma miss
consensu paragard surprisingli weak quarter sale
flat yoy forecast come heel two straight quarter
cc gain attribut slowdown combin decreas ad
spend channel inventori contract physician level
manag express confid mid-singl digit growth forecast paragard
go forward believ investor may hope given product
recent momentum sale appear highli depend promot ad
spend stage manag may balanc improv growth
maxim profit one lever intend pull aggress go forward
price paragard current cheaper nearest competitor iud
page analyst certif import disclosur
elsewher base offic surgic product busi flat pro forma basi
fertil segment pro forma post solid growth tough comp
fiscal manag reiter csi guidanc call underli
growth model coopersurg revenu pro
top line lower expect tax interest expens drove ep beat
cooper fiscal gross margin yoy
consensu partial off-set tight expens manag sg spend rose
yoy sale came street expect meanwhil
 spend declin yoy sale line consensu collect
result fiscal ebita margin yoy street
estim shortfal off-set lower expect interest expens
tax howev combin add ep drive earn beat vs
manag reiter revenu outlook increas low end
ep guidanc full year revenu expect come underli
growth still peg meanwhil adjust ep guidanc expect
increas low end adjust driven
combin reduc tax rate lower interest expens
favor fx partial off-set increas spend associ misit
continu see outlook fulli reflect stock current level
model call compani post ep underli
total revenu pro forma compar previou estim
respect meanwhil earn estim move
yoy share trade revis ntm ep
estim premium large-cap med-tech averag solid top
line growth rate vs large-cap group would seem argu premium
valuat compani earn growth appear like lag group averag
least next two year also view cooper outsiz exposur
consum categori believ could prove highli cyclic next econom
downturn argument multipl expans result maintain
page analyst certif import disclosur
straddl line healthcar consum product contact
len women health busi coopervis portfolio uniqu posit take
advantag two tailwind drive contact len market growth today shift
premium len materi particular silicon hydrogel increas popular
daili dispos lens recent year leverag broadest daili sih
offer market lead posit monthli sih categori continu
long histori above-market growth compani captur averag
market share per year sinc expect gain moder go forward
backdrop competit contact len market believ cooper
remain well posit sustain growth
elsewher paragard deal ad scale increment growth
coopersurg women health franchis often overlook investor
expect csi account overal revenu
growth fuel primarili compani invest
half dozen deal build lead posit ivf genet test
market follow acquisit paragard intrauterin devic
believ long-term fundament market appeal see
grow scale csi neg broader invest case complic
stori believ investor would prefer look sole contact len compani
share current trade ntm ep ntm ebitda
repres premium large-cap med-tech group averag price-to-earnings
large-cap group would seem argu slight premium valuat dont
see compani sustain bottom line growth trajectori meaning differenti
group averag also view cooper outsiz exposur
currenc swing rise interest rate consum categori believ could
prove highli cyclic next econom downturn argument multipl
expans result maintain neutral rate
upsid risk rate includ faster expect contact len market growth due
rise sih penetr daili len adopt increas share gain
busi better expect growth/accret paragard
downsid risk rate includ better anticip traction competit
contact len launch weaken macroeconom backdrop put pressur
cooper busi see discretionari med-tech market
potenti exposur strong dollar rise interest rate
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
compani report guggenheim secur llc estim
page analyst certif import disclosur
